Literature DB >> 1249801

Preparation and in vitro antifungal activities of some quinolizidine derived hemiaminals and beta-tert-amino sulfides.

R T LaLonde, A I Tsai, C J Wang, C Wong, G Lee.   

Abstract

New alpha-thiohemiaminals, 7alpha-phenylthio-7-epideoxynupharidin-6-ol, the diasteriomeric 7beta-phenylthiodeoxy-nupharidin-6-ol, and 3-methyl-3-methylthio-4-hydroxyquinolizidine, were prepared and reduced to the corresponding beta-tert-amino sulfides. The configuration at C-7 of the beta-tert-amino sulfides was determined by observing the direction of the solvent-induced shift of the C-7 methyl proton resonance. The configuration at C-7 of the new alpha-thiohemiaminals was established by correlations with the beta-tert-amino sulfides and confirmed, in the case of the deoxynupharidine derivatives, by circular dichroism and ascertaining the sterochemistry of deuteride incorporation upon sodium borodeuteride reduction of the alpha-thiohemiaminal. The in vitro antifungal activities of six compounds possessing the quinolizidine skeleton, including all the newly synthesized compounds as well as some previously reported ones, and amphotericin B were tested against several human pathogenic fungi. Besides amphotericin B, only the two deoxynupharidine alpha-thiohemiaminals were active, especially against Histoplasma capsulatum and Blastomyces dermatitidis. The observations indicate activity is derived from the 3-furyl group and the functionality from which alpha-thioimmonium ions can be produced.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1249801     DOI: 10.1021/jm00224a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  Synthesis and Sulfur Electrophilicity of the Nuphar Thiaspirane Pharmacophore.

Authors:  Norihiro Tada; Daniel J Jansen; Matthew P Mower; Megan M Blewett; Jeffrey C Umotoy; Benjamin F Cravatt; Dennis W Wolan; Ryan A Shenvi
Journal:  ACS Cent Sci       Date:  2016-06-13       Impact factor: 14.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.